化学发光企业跨界保健品，做成京东销量第一！

医业观察

02/12

有观点，有态度这是医业观察的第2691-3期文章作者：凯莉医业观察编辑近日，医业观察编辑凯莉刷朋友圈，被一则喜报吸引——来自南京仁迈生物金总朋友圈的官宣，该公司旗下的保健品做到了京东NMN类目销量第一！金总该朋友圈内容如下：愿望实现了销冠认证RealMind 双向臻护 NMN24000 登顶京东 NMN 类目销量第一上线即爆款，实力领跑抗衰新赛道！很多IVD同行都知道，仁迈生物的主业是做化学发光的...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2610807920"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610807920\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610807920?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-02-12 22:11","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2610807920","market":"hk","top_or_hot":-1,"title":"化学发光企业跨界保健品，做成京东销量第一！","media":"医业观察","content":"<div>\n<p>有观点，有态度这是医业观察的第2691-3期文章作者：凯莉医业观察编辑近日，医业观察编辑凯莉刷朋友圈，被一则喜报吸引——来自南京仁迈生物金总朋友圈的官宣，该公司旗下的保健品做到了京东NMN类目销量第一！金总该朋友圈内容如下：愿望实现了销冠认证RealMind 双向臻护 NMN24000 登顶京东 NMN 类目销量第一上线即爆款，实力领跑抗衰新赛道！很多IVD同行都知道，仁迈生物的主业是做化学发光的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021222532797a5faa9&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>化学发光企业跨界保健品，做成京东销量第一！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n化学发光企业跨界保健品，做成京东销量第一！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-12 22:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021222532797a5faa9&s=b><strong>医业观察</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>有观点，有态度这是医业观察的第2691-3期文章作者：凯莉医业观察编辑近日，医业观察编辑凯莉刷朋友圈，被一则喜报吸引——来自南京仁迈生物金总朋友圈的官宣，该公司旗下的保健品做到了京东NMN类目销量第一！金总该朋友圈内容如下：愿望实现了销冠认证RealMind 双向臻护 NMN24000 登顶京东 NMN 类目销量第一上线即爆款，实力领跑抗衰新赛道！很多IVD同行都知道，仁迈生物的主业是做化学发光的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021222532797a5faa9&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0588545904.SGD","symbol_name":"Eastspring Investments - Asian Equity Income ASDM SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021222532797a5faa9&s=b","article_id":"2610807920","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021222532797a5faa9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610807920","pubTimestamp":1770905495,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"有观点，有态度这是医业观察的第2691-3期文章作者：凯莉医业观察编辑近日，医业观察编辑凯莉刷朋友圈，被一则喜报吸引——来自南京仁迈生物金总朋友圈的官宣，该公司旗下的保健品做到了京东NMN类目销量第一！谁能想到，这家IVD企业，居然跨界扎进了保健品赛道，更厉害的是，刚出手就拿到了京东NMN类目销量第一！凯莉认为，IVD企业做化妆品，最大的底气莫过于“降维打击”的先天优势。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"89618":"京东集团-SWR","LU0588545904.SGD":"Eastspring Investments - Asian Equity Income ASDM SGD","LU0588545730.USD":"EASTSPRING INVESTMENTS ASIAN EQUITY INCOME \"ADM\" (USD) INC","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","IE00B3M56506.USD":"NEUBERGER BERMAN EMERGING MARKETS EQUITY \"A\" (USD) ACC","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","06618":"京东健康","LU0588545490.SGD":"Eastspring Investments - Asian Equity Income AS SGD","LU0531971595.HKD":"HSBC GIF CHINESE EQUITY \"AD\" (HKD) INC","LU0791591158.USD":"ALLSPRING  EMERGING MARKTES EQUITY INCOME \"I\" (USD) ACC","LU0052750758.USD":"富兰克林中国基金A Acc","LU0384037296.USD":"ALLIANZ ASIAN MULTI INCOME PLUS \"AT\" (USD) ACC","LU0488056044.USD":"Allianz Asian Multi Income Plus Cl AM DIS USD","IE00BGV7N243.SGD":"FSSA Global Emerging Markets Focus I Acc SGD","LU0345776255.USD":"NINETY ONE GSF ASIAN EQUITY \"A\" (USD) INC","LU0315178854.USD":"EASTSPRING INVESTMENTS ASIAN EQUITY INCOME \"A\" ACC","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU1224444064.USD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"AM\" (USDHDG) INC","LU0048580855.USD":"富达大中华区A","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","09618":"京东集团-SW","IE00B29SXG58.USD":"FSSA CHINA FOCUS \"I\" (USD) ACC","LU0293314216.USD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"A\" (USD) ACC","LU0359201612.USD":"贝莱德中国基金A2","LU1282651048.USD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"AMG\" (USD) INC","LU0348805143.USD":"ALLIANZ ENHANCED ALL CHINA EQUITY \"A\" (USD) INC","BK1502":"双十一","LU1720050803.USD":"安联全方位中国股票基金","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0149721374.USD":"HSBC GIF HONG KONG EQUITY \"AD\" INC","LU0231483743.USD":"abrdn SICAV I - ALL CHINA SUSTAINABLE EQUITY \"A\" (USD) ACC","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","LU0791590937.USD":"ALLSPRING  EMERGING MARKTES EQUITY INCOME \"A\" (USD)","BK1142":"互联网与直销零售","LU1282649810.SGD":"Allianz Asian Multi Income Plus Cl AMg DIS H2-SGD","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","BK1588":"回港中概股","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","BK1615":"港股-互联网","LU0211977185.USD":"EASTSPRING INVESTMENTS GREATER CHINA EQUITY \"A\" ACC","LU0163747925.USD":"EASTSPRING INVESTMENTS ASIAN EQUITY A ACC","BK1619":"稳定币概念","LU0499858602.USD":"NINETY ONE GSF ASIA PACIFIC EQUITY OPPORTUNITIES \"A\" (USD) ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","IE0032431581.USD":"PINEBRIDGE GREATER CHINA EQUITY \"A\" (USD) ACC","LU0868486357.SGD":"JPMorgan Funds - Emerging Markets Opportunities A (acc) SGD-H","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU1366334651.USD":"ALLSPRING EMERGING MARKETS EQUITY INCOME \"I\" (USD) INC","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0594300419.USD":"富达中国消费基金A","LU1770036033.HKD":"NINETY ONE GSF ASIAN EQUITY \"A\" (HKD) ACC","SG9999002828.SGD":"Eastspring Investments Unit Trusts - Dragon Peacock A SGD","LU0650527681.SGD":"Fidelity China Consumer A-SGD","BK1249":"综合零售","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","LU2257852520.SGD":"JPMorgan Funds - Asia Growth A (acc) SGD","LU0128522157.USD":"TEMPLETON ASIAN GROWTH \"A\" ACC","LU0320764755.SGD":"FTIF - Templeton Asian Growth A Acc SGD","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0871576103.HKD":"HSBC GIF CHINESE EQUITY \"AC\" (HKD) ACC","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0431992006.USD":"摩根大通新兴市场机会A（acc）","LU1282649067.USD":"ALLIANZ ASIAN MULTI INCOME PLUS \"AMG\" (USD) INC A","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0865486749.SGD":"Eastspring Investments - Asian Equity Income AS SGD-H","LU0499858438.USD":"NINETY ONE GSF ASIA PACIFIC EQUITY OPPORTUNITIES \"A\" (USD) INC","LU0469268626.HKD":"AB FCP I-ASIA EX JAPAN EQUITY PTF(AD","LU1044875133.USD":"天利亚洲反向股票 AU Acc","SG9999001226.SGD":"UNITED SUSTAINABLE ASIA TOP 50 \"A\" (SGD) ACC","LU0259732245.USD":"EASTSPRING INVESTMENTS DRAGON PEACOCK A","LU0029875118.USD":"TEMPLETON ASIAN GROWTH \"A\" INC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","BK1591":"就地过年概念","LU0828237510.HKD":"SCHRODER ISF BIC (BRAZ IN CH)\"A\" (HKD) ACC","LU0672654166.SGD":"FTIF - Templeton Asian Growth A (acc) SGD-H1","LU0228659784.USD":"施罗德金砖四国基金","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","LU0051755006.USD":"摩根大通中国A (dist)","LU0370786039.SGD":"Fidelity Greater China A-SGD","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU0543330483.HKD":"TEMPLETON ASIAN GROWTH \"A\" (HKD) ACC","LU1044876610.USD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"ZU\" (USD) ACC","LU1366334578.USD":"ALLSPRING EMERGING MARKETS EQUITY INCOME \"A\" (USD) INC","LU1481107354.HKD":"HSBC GIF HONG KONG EQUITY \"AD\" (HKD) INC","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU1642822792.SGD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"A\" (SGD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU1044874839.SGD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"AGH\" (SGDHDG) ACC","LU0084288322.USD":"Natixis Asia Equity RD USD","LU0164865239.USD":"HSBC GIF CHINESE EQUITY \"AC\" (USD) ACC","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","BK1610":"ETF&股票定投概念","LU1282651121.HKD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"AMG\" (HKD) INC","BK1575":"同股不同权","LU0345775950.USD":"NINETY ONE GSF ASIAN EQUITY \"A\" (USD) ACC","LU0228367735.SGD":"Eastspring Investments - Asian Equity Fund AS SGD","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0164880469.USD":"HSBC GIF HONG KONG EQUITY \"AC\" ACC"},"translate_title":"Cross-border health care products of chemiluminescence enterprises have become the number one seller in JD.com!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"89618":0.6,"09618":0.9,"06618":1.87},"content_text":"有观点，有态度这是医业观察的第2691-3期文章作者：凯莉医业观察编辑近日，医业观察编辑凯莉刷朋友圈，被一则喜报吸引——来自南京仁迈生物金总朋友圈的官宣，该公司旗下的保健品做到了京东NMN类目销量第一！金总该朋友圈内容如下：愿望实现了销冠认证RealMind 双向臻护 NMN24000 登顶京东 NMN 类目销量第一上线即爆款，实力领跑抗衰新赛道！很多IVD同行都知道，仁迈生物的主业是做化学发光的，深耕体外诊断领域10年，踏踏实实做试剂、做设备，在行业里也算有口皆碑。据仁迈生物公司官网信息，仁迈生物专注于“一老一小”特色检测试剂项目以及末梢血全血全自动检测平台的研发、生产和销售。检测试剂产品包括儿童营养及生长发育、危急重症、脑损伤、阿尔茨海默症、血栓、骨质疏松检测等临床特色项目，共获得NMPA产品注册证70+项，CE认证100+项。累计装机数量800+台，覆盖全国25个省，客户中三甲医院占比约50% 。仁迈生物目前是罗氏诊断和金赛药业的合作伙伴，已完成C轮融资，投资方包括红杉资本等知名机构。谁能想到，这家IVD企业，居然跨界扎进了保健品赛道，更厉害的是，刚出手就拿到了京东NMN类目销量第一！编辑凯莉特意去京东搜了一下，果然，这款来自仁迈生物的NMN产品，居于类目销量榜首，评论区很多消费者的好评，“性价比拉满”，“不愧是医疗背景企业做的，很有效果”。2026年1月21日，医业观察 编辑凯莉注意到 不菲BuFei 公众号发布文章，推出针对油性肌肤显性问题的全周期抗衰护肤品套装。而这家企业正是IVD行业龙头企业迈克生物参与投资的企业。参考迈克投资的企业，出化妆品了！IVD企业跨界美妆在业内早已不算是“新闻”。热景生物旗下“蔻生元”“EXOMICS茵颂”双品牌齐发力，依托植物外泌体技术推出医研级抗衰产品，天猫旗舰店已形成完整产品矩阵，甚至联合行业协会发布技术白皮书树立标准；热景生物：新获23项国内外医疗器械及化妆品资质认证博科生物也高调布局美妆原料与护肤品研发，凭借生物实验室优势探索成分创新。IVD企业集体跨界美妆，绝非一时兴起，而是产业逻辑与市场需求共同作用的必然结果。IVD行业这几年面临集采的压力，企业为了生存发展，跨界经营无可厚非。凯莉认为，IVD企业做化妆品，最大的底气莫过于“降维打击”的先天优势。从监管适配性、技术复用性和市场需求匹配的角度，都非常契合。其一，监管适配性强医疗器械与化妆品均由国家药监局监管，尽管二者在上市前审批、质量体系要求上存在差异——如医疗器械强制符合QSR体系，化妆品以备案制为主，但IVD企业长期浸润在严格的合规体系中，对原料把控、生产规范、标签合规的理解远超普通美妆品牌，这种“医疗级严谨”自带安心属性，恰好击中消费者对护肤品安全性的核心诉求。其二，技术复用性高IVD行业对人体生理机能、生物成分的研究深度，是普通美妆企业难以企及的。热景生物将纳诺革装载技术应用于抗衰产品，迈克依托生物检测技术对肌肤问题的精准洞察，本质上都是将IVD的核心技术平移至美妆领域。这种技术赋能下的产品，能构建差异化竞争壁垒。其三，市场需求精准匹配“理性消费”当下消费者追求“健康与美”的双重需求，医疗背景加持的保健品、护肤品，天然契合这种消费趋势。有医疗技术撑腰、有合规体系把关，才能真正让消费者买得放心、用得安心，这或许就是IVD企业跨界最大的底气。为仁迈生物点赞！作者：凯莉","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}